Press releases

4 September 2012

Verona Pharma reports bronchodilator data with RPL554 in COPD patients at the 2012 European Respiratory Society

4 September 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, today announces the completion and reporting of data from a clinical trial with its lead drug candid…

Read more

3 September 2012

New data on RPL554 in COPD to be Presented at ERS Annual Congress

3 September 2012 - London, UK – Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, announces that new data on the Company’s lead compound RPL554 will be presented at this year’…

Read more

28 August 2012

US Patent Granted for Verona Pharma’s RPL554

28 August 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the drug discovery company with first-in-class drugs to treat respiratory diseases, today announces that the United States Patent and Trademark Office has granted a new patent for the Company’s lead…

Read more

12 July 2012

Verona Pharma Initiates Dosing in Clinical Trial to Investigate Anti-inflammatory Properties of RPL554

9 July 2012 - London, UK - London, UK - Verona Pharma plc (AIM: VRP.L), the biotechnology company focused on developing novel treatments for chronic respiratory diseases, today announces that it has commenced a new trial with its lead drug candidate, the dual PDE…

Read more

9 March 2012

Verona Pharma appoints Manchester clinical research facility to carry out first UK-based anti-inflammatory clinical trial with RPL554


Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us